×
Nature's Sunshine Products Net Profit Margin 2010-2024 | NATR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Nature's Sunshine Products net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
View More
Nature's Sunshine Products Net Profit Margin 2010-2024 | NATR
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Profit Margins
Gross Margin
Operating Margin
EBITDA Margin
Pre-Tax Margin
Net Margin
Nature's Sunshine Products net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$78.6B
Takeda Pharmaceutical (TAK)
$44.1B
Merck (MKKGY)
$21.2B
Astellas Pharma (ALPMY)
$20.4B
Sandoz Group AG (SDZNY)
$19.7B
United Therapeutics (UTHR)
$18B
Summit Therapeutics (SMMT)
$15.6B
Neurocrine Biosciences (NBIX)
$12.6B
Shionogi (SGIOY)
$12.5B
Catalent (CTLT)
$10.9B
Madrigal Pharmaceuticals (MDGL)
$7.7B
Jazz Pharmaceuticals (JAZZ)
$7.4B
Orion OYJ (ORINY)
$6.8B
Ionis Pharmaceuticals (IONS)
$6.1B
Corcept Therapeutics (CORT)
$5.7B
Crinetics Pharmaceuticals (CRNX)
$4.8B
PTC Therapeutics (PTCT)
$3.3B
Dyne Therapeutics (DYN)
$2.9B
Catalyst Pharmaceuticals (CPRX)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.7B
Soleno Therapeutics (SLNO)
$2.5B
NewAmsterdam Pharma (NAMS)
$2B
Recursion Pharmaceuticals (RXRX)
$1.9B
Centessa Pharmaceuticals (CNTA)
$1.8B
Harrow (HROW)
$1.8B
Ocular Therapeutix (OCUL)
$1.7B
Xencor (XNCR)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.6B
ARS Pharmaceuticals (SPRY)
$1.6B